Intercept Pharmaceuticals clinical trials

Acquired by Alfasigma S.p.A., Nov 8, 2023 · source ↗

The registry lists 22 studies whose lead sponsor is Intercept Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 22 of 22. All Alfasigma S.p.A. studies →

• Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCTerminatedNCT04594694Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCCompletedNCT05239468Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedNCT06121375Phase 2/3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibrateTerminatedNCT06488911Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted after Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) StudyTerminatedNCT05639543Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsCompletedNCT05292872

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentTerminatedNCT02548351Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)TerminatedNCT00550862Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompletedNCT03439254Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsWithdrawnNCT05293938

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Obeticholic Acid in Pediatric Subjects With Biliary AtresiaTerminatedNCT05321524Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisTerminatedNCT02308111Phase 4

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentTerminatedNCT03633227Phase 4

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisCompletedNCT01865812Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)CompletedNCT02177136Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)CompletedNCT00570765Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisCompletedNCT01473524Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)CompletedNCT02633956Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)CompletedNCT01914562Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)CompletedNCT01933503Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Hepatic Impairment Trial of Obeticholic AcidCompletedNCT01904539Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of INT-747 in Patients With Diabetes and Presumed NAFLDCompletedNCT00501592Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.